Rybelsus (semaglutide oral) / Novo Nordisk - LARVOL DELTA

Orforglipron Compared with Oral Semaglutide in Type 2 Diabetes: Results from ACHIEVE-3 (ADA 2026) - No abstract available

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Phase 3 Clinical Protocol Evaluating the Safety and Efficacy of NA-931 Alone and in Combination with Oral Semaglutide for the Treatment of Obesity (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • Clinical protocol • Combination therapy • P3 data • Metabolic Disorders • Obesity

Nationwide Real-World Retrospective Study of Oral Semaglutide Use in Patients with Type 2 Diabetes in Finland (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Real-world • Real-world evidence • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Long Duration of Action of an Oral Semaglutide Administered via the Intestine in Healthy Humans (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • Metabolic Disorders

Comparing Major Adverse Kidney Events (MAKE) among New Users of Oral Semaglutide (SEMA) vs. Select Oral Antidiabetic Medications (ADMs) among U.S. Adults with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD) (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Adverse events • Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of QLG1090 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes (clinicaltrials.gov) - P3 | N=478 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

New P3 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: University of Florida | N=30 ➔ 20

Enrollment change • Endometrial Adenocarcinoma • Endometrial Cancer • Long-acting Reversible Contraceptives • Obesity • Oncology • Solid Tumor

ORAL SEMAGLUTIDE FOR WEIGHT MANAGEMENT AND GASTROINTESTINAL SAFETY IN METABOLIC DISEASE; A META-ANALYSIS AND NARRATIVE LIVER OUTCOME SYNTHESIS (APASL 2026) - No abstract available

Retrospective data • Metabolic Disorders

Efficacy of oral semaglutide in overweight- obese patients with metabolic dysfunction-associated steatotic liver disease (MASLD) related compensated advanced chronic liver disease (cACLD) - Results of first randomized controlled trial (EASL 2026) - No abstract available

Clinical • Metastases • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity

A Systematic Review and Meta-Analysis of Efficacy and Safety of Liraglutide in Patients with Type 2 Diabetes Mellitus. (PubMed, Diabetes Metab Syndr Obes) - "When compared with oral semaglutide, exenatide, dulaglutide, lixisenatide, and albiglutide, liraglutide showed comparable efficacy. Liraglutide 1.2 mg showed a numerically lower incidence of nausea and similar rates of vomiting compared with other GLP-1RAs. Liraglutide 1.2 mg and 1.8 mg doses improve weight and glycemic outcomes with a favourable safety profile, supporting its role as an effective therapeutic option for comprehensive management of T2DM with comorbid obesity."

Journal • Retrospective data • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

HARMONIZED META-ANALYSIS OF GLP-1 RECEPTOR AGONIST CARDIOVASCULAR OUTCOME TRIALS: CONSISTENT REDUCTION IN 3-POINT MACE (ACC 2026) - " To assess GLP-1RA effects on 3-point MACE (CV death, nonfatal MI, nonfatal stroke) and the impact of endpoint harmonization, we meta-analyzed eight placebo-controlled CV outcome trials: ELIXA (lixisenatide), LEADER (liraglutide), SUSTAIN-6 (semaglutide s.c.), EXSCEL (exenatide), HARMONY (albiglutide), REWIND (dulaglutide), PIONEER-6 (oral semaglutide), and AMPLITUDE-O (efpeglenatide). Across >60,000 T2D patients, GLP-1RAs reduced 3-point MACE by ~14%. By harmonizing endpoints and eliminating trial-level variation, this analysis clarified a consistent class effect, contrasting prior heterogeneous reports and reinforcing GLP-1RAs as a cornerstone of ASCVD prevention."

Retrospective data • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

PROJECTED REDUCTION IN MAJOR ADVERSE CARDIOVASCULAR EVENTS AMONG HIGH-RISK U.S. ADULTS WITH TYPE 2 DIABETES ELIGIBLE FOR ORAL SEMAGLUTIDE: A SOUL TRIAL BASED ANALYSIS USING NHANES 1988-2018 CYCLES (ACC 2026) - "Widespread use of oral semaglutide among eligible U.S. adults with type 2 diabetes could substantially reduce cardiovascular events. These findings support its potential as a scalable, population-level cardiometabolic intervention and highlight the need for system-level strategies to enhance access and uptake."

Adverse events • Clinical • Cardiovascular • Diabetes • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

EFFECT OF ORAL SEMAGLUTIDE VERSUS PLACEBO ON FIRST AND TOTAL MACE IN SOUL TRIAL PARTICIPANTS WITH T2D AND ASCVD AND/OR CKD (ACC 2026) - P3 | "Oral semaglutide was associated with risk reduction in first and total 3P, 4P and 5P MACE vs placebo and reduced the overall burden of MACE in participants in the SOUL trial."

Clinical • Acute Coronary Syndrome • Cardiovascular • Chronic Kidney Disease • Myocardial Infarction • Type 2 Diabetes Mellitus

Eligibility for glucagon-like-peptide-1 agonists in a secondary care chronic kidney disease cohort. (UKKW 2026) - "Only 31 patients in the cohort (1.2%) were receiving GLP1A : 10 oral Semaglutide and 21 subcutaneous GLP1As... Obesity is a highly prevalent co-morbidity amongst our CKD cohort. 35% of the cohort may be eligible for GLP1A based on current NICE guidance, while only 1.9% fulfilled stricter local criteria. However, only 1.2% were receiving GLP1A or GIP+GLP1A."

Cardiovascular • Chronic Kidney Disease • Diabetes • Focal Segmental Glomerulosclerosis • Genetic Disorders • Glomerulonephritis • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Exploring the use of GLP-1 and GIP/GLP-1 medications in people on renal replacement therapy, an observational cohort study. (UKKW 2026) - "Thirty-five were on HD (3.1% of 1117 patients on HD) and five on PD (2.6% of 191 patients on PD)...Semaglutide injection was the most prescribed medication (28%), followed by Tirzepatide (23%), Semaglutide tablets (20%), Liraglutide (17%), and Dulaglutide (12%)... GLP-1 and GLP-1/GIP medications are being used in the local RRT population, with over half of the patients showing meaningful weight loss and increases in transplant eligibility. Better integration of dietetic care may enhance outcomes, both in terms of weight loss but also nutritional adequacy."

Observational data • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Sarcopenia • Type 2 Diabetes Mellitus

Impact of Semaglutide 2.4 mg and Oral Semaglutide 25 mg on QoL in Women With Obesity: A {Post Hoc} Analysis of the STEP and OASIS Programmes by Menopausal Status (ECO 2026) - No abstract available

Clinical • Retrospective data • Genetic Disorders • Obesity

A case of type 2 diabetes with spinal and bulbar muscular atrophy treated with oral semaglutide while sparing muscle reduction for two years: a case report with literature review. (PubMed, Diabetol Int) - "Semaglutide has demonstrated beneficial effects in patients with type 2 diabetes; however, its long-term impact on skeletal muscle remains uncertain, particularly in individuals with multiple risk factors for muscle decline. Importantly, skeletal muscle mass and strength were relatively preserved, with only a minor annual decrease in muscle mass (- 0.1 kg/year), consistent with changes reported in previous studies of semaglutide-treated patients without neuromuscular conditions. To our knowledge, this is the first reported case describing the use of semaglutide in a patient with diabetes and SBMA under leuprorelin treatment, suggesting the potential utility of GLP-1 receptor agonists in managing metabolic parameters in individuals at high risk for muscle decline."

Journal • Diabetes • Metabolic Disorders • Muscular Atrophy • Type 2 Diabetes Mellitus

EFFICACY OF ORAL SEMAGLUTIDE IN AN ADOLESCENT WITH HNF1A-MODY (MATURITY-ONSET DIABETES OF THE YOUNG) (ATTD 2026) - "Emerging evidence suggests that glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment may also be considered in MODY subtypes with insulin deficiency. We present the case of an 18-year-old non-obese female patient diagnosed with HNF1A-MODY at the age of 15, previously treated with gliclazide. This case suggests that oral semaglutide may be an effective and safe alternative to sulfonylureas in patients with HNF1A-MODY, offering improved glycemic control without significant side effects."

Clinical • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • HNF1A

IMPACT OF ORAL SEMAGLUTIDE AND EMPAGLIFLOZIN ON METRICS DERIVED FROM INTERSTITIAL GLUCOSE MONITORING IN PATIENTS WITH TYPE 2 DIABETES: A PRAGMATIC STUDY (ATTD 2026) - "Both drugs are effective and safe in improving glycemic control and kidney function metrics. The integrated discussion with recent authors highlights that SGLT2 inhibitors and GLP1RAs offer complementary benefits, suggesting the importance of individualizing therapy and considering appropriate titration in Venezuelan clinical practice."

Clinical • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

THE BLOCKBUSTER BATTLE IN OBESITY: DO NEWER SEMAGLUTIDE DOSES CLOSE THE GAP? A TIME-COURSE MODEL-BASED NMA (ISPOR 2026) - "Recent approval of oral semaglutide (25mg/day) and availability of higher-dose subcutaneous (SC) semaglutide (7.2mg) has further expanded the treatment landscape. In this time-course MBNMA, higher-dose semaglutide narrowed the efficacy gap versus tirzepatide for TBWL% over two years, with overlapping CrIs between treatments. These findings provide robust comparative evidence to guide long-term obesity management and dose selection, emphasizing the potential of higher-dose semaglutide and tirzepatide for maximizing treatment efficacy."

Genetic Disorders • Obesity

COST-EFFECTIVENESS ANALYSIS OF ORFORGLIPRON AND SEMAGLUTIDE FOR THE TREATMENT OF ADULTS WITH OBESITY IN THE UNITED STATES (ISPOR 2026) - "OBJECTIVES: To conduct a cost-effectiveness analysis comparing oral semaglutide and orforglipron as adjuncts to lifestyle modification (LSM) versus LSM alone from a healthcare sector perspective in the US adult population with obesity. We used a state-transition Markov model to estimate incremental cost-effectiveness ratios (ICERs), quality-adjusted life-years (QALYs), disease-free life-years (DFLYs), and costs over a 10-year time horizon. Compared to LSM alone, semaglutide plus LSM and orforglipron plus LSM were not cost-effective at the anticipated net price of $6,829 for each product, and a WTP threshold of $120,000 per QALY gained. Our findings suggest that both drugs may offer greater value in groups with a higher baseline risk; hence, policymakers and payers may consider risk-targeted coverage or value-based pricing to improve affordability."

Clinical • Cost effectiveness • HEOR • Genetic Disorders • Obesity

Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. (PubMed, Lancet) - P3 | "In individuals with type 2 diabetes inadequately controlled with metformin, orforglipron 12 mg and 36 mg was non-inferior and superior to semaglutide 7 mg and 14 mg with respect to the mean change in HbA1c from baseline to 52 weeks. Although the safety profiles of both orforglipron and semaglutide were generally consistent with the GLP-1 receptor agonist class, the incidence of gastrointestinal events, discontinuations due to adverse events, and mean increase in pulse rate were higher with orforglipron than oral semaglutide."

Head-to-Head • Journal • P3 data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Top-line Results from evoke and evoke+: Two Phase 3, Randomized, Placebo-controlled Trials of Semaglutide in Participants with Early-stage Symptomatic Alzheimer's Disease (AAN 2026) - P3 | "Participants received semaglutide 14mg orally or placebo for 3 years with a 5-week follow-up period. Results from evoke and evoke+ will be presented at a scientific conference in 2026. Novo Nordisk thanks evoke and evoke+ participants, their families, investigators, site personnel and everyone involved in the trials.Previously presented at CTAD25 and published in JPAD (Cummings et al. 2025; DOI:TBC )"

Clinical • P3 data • P3 data: top line • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Inflammation

GLP-1 Receptor Agonists in Alzheimer's Disease: A Living Systematic Review Integrating Clinical Trials, Real-world Evidence, and Translational Feasibility (AAN 2026) - "Their dual metabolic and neuroprotective actions position them as leading repurposed candidates for Alzheimer's disease (AD).Design/ This living systematic review synthesized phase 2/3 trials and large real-world studies of liraglutide, semaglutide, and exenatide in MCI and AD (2000–2025)...Semaglutide (oral daily; EVOKE / EVOKE+) has the highest statistical power (N ≈ 1,800 each); results are expected in 2025... GLP-1 RAs currently represent the most mature, mechanistically coherent repurposed strategy for AD. Integrating trial and real-world evidence underscores consistent neuroprotective trends across settings. Pending phase 3 readouts will clarify disease-modifying potential."

Clinical • HEOR • Real-world • Real-world evidence • Review • Alzheimer's Disease • CNS Disorders • Dementia • Diabetes • Genetic Disorders • Inflammation • Metabolic Disorders • Obesity

BP45703: A Study to Compare Different Doses of RO7795081 with a Placebo or Semaglutide in People with Type 2 Diabetes (clinicaltrialsregister.eu) - P1/2 | N=74 | Recruiting | Sponsor: F. Hoffmann-La Roche AG

New P1/2 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus